慢性鼻-鼻窦炎患者药物治疗的生存质量及相关研究

目的 使用鼻窦炎症状视觉模拟量表(VAS)及鼻窦炎专用量表-鼻腔鼻窦结局测试20(SNOT-20)中文版评价慢性鼻-鼻窦炎患者药物治疗前与治疗后不同时间的生存质量(QOL),探讨药物治疗对患者QOL的影响。 方法 收集慢性鼻-鼻窦炎患者100例作为实验组,给予药物联合治疗12周,每4周进行一次VAS评分及SNOT-20评分。另收集100例健康体检者作为对照组,进行一次相同的评分。分析实验组治疗前后及停药后患者VAS评分、SNOT-20评分的变化及与对照组的差异。 结果 实验组治疗前后及停药后VAS评分差异具有统计学意义(F=38.39,P<0.01)。实验组治疗12周后与对照组VAS评分比较差异具有统计学意义(t=7.93,P<0.01)。实验组VAS、CT评分于治疗后5个症状占比分别有所下降,每种症状的VAS、CT评分也有所下降。实验组治疗前后及停药后SNOT-20评分经单因素方差分析显示差异具有统计学意义(F=27.93,P<0.01)。实验组治疗12周后与对照组SNOT-20评分比较差异具有统计学意义(t=19.93,P<0.01)。实验组于治疗后各症状占比人数分别有所下降,每种症状的SNOT-20评分也有所下降。 结论 药物治疗作为慢性鼻-鼻窦炎的首选治疗方式,可有效改善患者的QOL,但长期小剂量使用的远期疗效尚有待进一步证实。

Investigation of quality of life on chronic rhinosinusitis following medication

Objective To evaluate chronic rhino-sinusitis medication before treatment and quality of life (QOL)at dif-ferent times after treatment and to investigate the drug therapy on QOL of patients.Methods Using sinusitis symptom visual analog scale (VAS)and sinusitis special scale-sinonasal outcome Test 20 (SNOT-20),we collect 100 patients with chronic rhinitis-sinusitis as the experimental group receiving 12 weeks combination therapy drugs,once every four weeks,and another 100 healthy volunteers as the control group.Results By univariate analysis,the VAS score showed a significant difference (F =38.39,P <0.01 )before and after treatment in the experimental group,and it showed a significant difference (t =7.93,P <0.01)between the 12-week after treatment group and the control group;After the drug treatment,VAS and CT score of 5 symptoms accounted decreases and each symptom rate also declined. By univariate analysis,the SNOT-20 score also showed a significant difference (F =27.93,P <0.01)before and after treatment in the experimental group,and it showed a significant difference (t =19.93,P <0.01)between the 12-week after treatment group and the control group;After the drug treatment,patents with each symptom accounted decrease and each symptom rate also declined.Conclusion Drug treatment can effectively improve the QOL chronic rhinitis sinusi-tis,whether needing long-term low-dose use remains further confirmation.